#PrecisionMedicine company, empowering #oncologists with personalized treatment options for patients with #cancer
San Diego, CA
Joined November 2015
- Tweets900
- Following2.9K
- Followers1.4K
- Likes814
CureMatch retweeted
๐ฅ๐ฒ๐ด๐ถ๐๐๐ฒ๐ฟ ๐ป๐ผ๐: bit.ly/WINSympo2026website
๐ง๐ต๐ฒ ๐ฐ๐ผ๐๐ป๐๐ฑ๐ผ๐๐ป ๐ถ๐ ๐ผ๐ป ๐ณ๐ผ๐ฟ ๐ช๐๐ก ๐ฆ๐๐บ๐ฝ๐ผ๐๐ถ๐๐บ ๐ฎ๐ฌ๐ฎ๐ฒ.
How are AI, genomic profiling and next-generation therapeutics changing the future of precision oncology?
The Industry Perspectives program brings together leaders from across life sciences to explore emerging technologies, novel drug targets and industry-academia collaboration.
๐๐ ๐ฎ๐ป๐ฑ ๐๐ต๐ฒ ๐๐ต๐ฎ๐ป๐ด๐ถ๐ป๐ด ๐๐ฟ๐ผ๐ป๐๐ถ๐ฒ๐ฟ ๐ผ๐ณ ๐ฃ๐ฟ๐ฒ๐ฐ๐ถ๐๐ถ๐ผ๐ป ๐ ๐ฒ๐ฑ๐ถ๐ฐ๐ถ๐ป๐ฒ
> Dr. David Spetzler, MS, PhD, MBA - Caris Life Sciences, Paradise Valley, AZ, USA
Followed by:
๐๐ป๐ฑ๐๐๐๐ฟ๐ ๐ฃ๐ฒ๐ฟ๐๐ฝ๐ฒ๐ฐ๐๐ถ๐๐ฒ๐: ๐๐ฒ๐ป๐ผ๐บ๐ถ๐ฐ ๐ฃ๐ฟ๐ผ๐ณ๐ถ๐น๐ถ๐ป๐ด, ๐ก๐ฒ๐
๐-๐๐ฒ๐ป๐ฒ๐ฟ๐ฎ๐๐ถ๐ผ๐ป ๐๐ฟ๐๐ด๐ & ๐ฃ๐ฟ๐ฒ๐ฐ๐ถ๐๐ถ๐ผ๐ป ๐ข๐ป๐ฐ๐ผ๐น๐ผ๐ด๐
Featuring:
> Mr. Zach Boyd, MS, PhD - J&J, Thousand Oaks, CA, USA
> Mr. John Tarantino, JD - Iylon, USA
> Dr. David Spetzler, MS, PhD, MBA - Caris Life Sciences, Paradise Valley, AZ, USA
> Mr. Navid Alipour, JD/MBA - CureMatch, USA
> Prof. Nesrin Erkol, PhD - Vaccizone Biotechnology, Turkey
> Mr. Bradley Sander - P53 Therapeutics, USA
> Dr. Emile Youssef, MD, PhD - P53 Therapeutics, USA
Join the international precision oncology community in ๐ฃ๐ฟ๐ผ๐๐ถ๐ฑ๐ฒ๐ป๐ฐ๐ฒ, ๐ฅ๐ต๐ผ๐ฑ๐ฒ ๐๐๐น๐ฎ๐ป๐ฑ, ๐ข๐ฐ๐๐ผ๐ฏ๐ฒ๐ฟ ๐ฎ-๐ฏ, ๐ฎ๐ฌ๐ฎ๐ฒ.
โณ Register now and be part of the conversation.
#WINSympo2026 #PrecisionOncology #CancerResearch #AIinHealthcare #Genomics #LifeSciences
CureMatch retweeted
So incredibly proud of our @CureMatch team! The hard work put in every day, by so many to deliver better clinical decision support, with our amazing cofounder @Dr_R_Kurzrock blazing a path to prolong lives and save lives.
linkedin.com/posts/precisionโฆ
CureMatch retweeted
Bringing experts together from across the nation to help rare cancer patients
Have you ever wondered what takes place in a TCF-001 TRACK Virtual #MolecularTumorBoard meeting?
Watch to learn how biomarker testing and multi-disciplinary expertise come together to uncover treatment options for difficult-to-treat #RareCancers
targetcancer.short.gy/RCTT-2โฆ
CureMatch retweeted
We've officially announced the next evolution of #cmAngioยฎ. Building on FDA-cleared BAC detection, cmAngio now detects, quantifies & contextualizes Breast Arterial Calcification (BAC). New: BAC quantification, Age-Based Percentile & Prevalence.
einpresswire.com/article/934โฆ
CureMatch retweeted
One gene/one target has a ceiling in complex cancers. Either treat earlier before complex evolution or give biomarker matched combinations or both
Pleasure to work with @VivekSubbiah on this concept
โญ๏ธPleased to share our paper ๐๐ผBeyond one gene, one target: Next-generation precision oncology: Trends in Cancer @trendscancer @CellCellPress @CellPressNews @OncoAlert @Dr_R_Kurzrock
cell.com/trends/cancer/fulltโฆ
CureMatch retweeted
On days like today I think about the future and strategize.
Following progress over decades I am excited to continue shaping the future of precision oncology clinical practice with research innovations, technology breakthroughs, education and training to help patients in Rhode Island and globally.
It is a powerful motivator to see discoveries in my lab over 3 decades culminate in FDA approval of ONC201/dordaviprone less than a year ago in 2025 to treat these aggressive H3K27M-mutated diffuse gliomas.
This unique and amazing precision oncology story is only the beginning of what has to happen for patients building on lessons learned. There are many novel drugs and drug combinations waiting to be translated for brain and other tumor types.
Technologies and AI are still fairly primitive but important progress is being made.
Looking forward to the 2026 WIN Symposium on October 2-3, 2026 at the Rhode Island Convention Center in Providence. It should be a great event with the world-class faculty in attendance. Register for the event at mcigroup-winsymposium2026.evโฆ
@BrownUnivHealth @WIN_Consortium @SWOG @AmericanCancer @bcarneiro7 @LiangChengMD @carisls @Dr_R_Kurzrock @JazzPharma @AshleySumrall @LiaTsimberidou @SewantiLimaye @LussierY @DrRoyHerbst @jrgralow @BrownUniversity @BrownOncology @TempusAI @CureMatch @JiaJennyLiu @billdahutmd @charlesbalchmd @ASCO @VivekSubbiah @SenduraiMani @SeanLawler20
CureMatch retweeted
A community oncologist texted me Sunday night about a tough GU Oncology case. I get these every week โ and I always answer, because behind each one is a patient.
But a text helps one doctor, once. 85% of US cancer patients are treated in the community โ by physicians who see every tumor type, keeping pace with 50+ new approvals a year. No one does that alone.
That's why I use @PrimumHealthIncโIt is vetted experts, real cases, nearby trials โ free for physicians. 9,000+ inquiries in; 57% changed treatment.
primum.co
CureMatch retweeted
For about $2000 CureMatch will do something similar (but without the creation of a specific drug). Get a genome analysis of your cancer tumor, send it to CureMatch and theyโll use AI to give you a tailored drug combination therapy to attack the tumor.
Unlike alternatives, Curematch will recommend off label and clinical drugs (eg. A drug FDA approved for stomach cancer might attack the same tumor aberration of your colon cancer for instance).
CureMatch retweeted
Despite therapeutic advances, ~50% of patients with advanced melanoma die from metastatic disease. @CureMatch helps identify actionable molecular alterations to guide personalized treatment. This is off of the #NGS lab work as our input. More at: curematchdirect.com
CureMatch retweeted
We have GBM patient we assisted, 5-6 years out in remission! Definition of insanity is doing the same thing expecting different results.
CureMatch retweeted
Good for him. We use the same therapy as in 2005, when Stupp was published, and everyone is dead at 3 years. And itโs not a nice death either. Another example of โdo anything but standard of careโ.
Every GBM patient should be offered a clinical trial in first line
Iโm new to the Glioblastoma therapy field, but when the inventor of the Stupp protocol writes an editorial in @TheLancetOncol pleading for progress after 20 years, we need all hands on deck! @roger_stupp @MKhasraw @AshishHShah4 @SylvesterCancer #GBMsm
CureMatch retweeted
Every GBM Patient Should be Offered a Clinical Trial in First Line - Razelle Kurzrock (@Dr_R_Kurzrock)
oncodaily.com/voices/razelleโฆ
#OncoDaily #Oncology #Cancer #Health #Medicine #MedX #MedTwitter
CureMatch retweeted
Here we go again. Treat early
New from #AACR26: A small clinical trial (8-person) at MSK is showing promise for people with early-stage #rectalcancer whose tumors are driven by excessive amounts of a protein called HER2 (human epidermal growth factor receptor 2).
The trial, led by MSK gastrointestinal medical oncologists Dr. @MikeFooteMD and Dr. @AndreaCercek, suggests that many of these patients may be successfully treated using targeted therapies to avoid surgery, resulting in fewer side effects and better quality of life during and after treatment.
Learn more about this research: bit.ly/4tiSVvL @aacr
CureMatch retweeted
Three (of four) reported patients with GBM remain in radiographic and clinical complete remission at 39+, 48 and 52+ months with personalized biomarker-matched targeted therapy
Precision oncology N-of-1 (E=mc2) comes for brain tumors
innovationsjournals-jipo.kglโฆ
pubmed.ncbi.nlm.nih.gov/4183โฆ
CureMatch retweeted
From our โฆ@CureMatchโฉ founder โฆ@Dr_R_Kurzrockโฉ: amazing results using our clinical decision support! Patients years in remission with aggressive brain cancers. innovationsjournals-jipo.kglโฆ
CureMatch retweeted
We would like to inform you that your post has been published on OncoDaily. Thank you for sharing.
oncodaily.com/voices/razelleโฆ
CureMatch retweeted
At @CureMatch, we are honored to have the support of esteemed oncologists like Dr. @VivekSubbiah. This study he calls โPrecision oncologyโs E = MC 2โ is the premise of CureMatch, founded by our very own @Dr_R_Kurzrock